Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

How I use Maintenance Therapy in Acute Myeloid Leukemia

Gail J. Roboz, Jonathan Canaani

Blood blood.2024024010.

https://doi.org/10.1182/blood.2024024010

Published: 2024

Journal Articles

Gilteritinib and Venetoclax for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia - a Real-World Multicenter Retrospective Study

Eitan Kugler, Inbar Cohen, Ron Ram, Jonathan Canaani, Irina Amitai, Liat Shargian, Boaz Nachmias, Baher Krayem, Avraham Frisch, Itay Levi, Luiza Akria, Pia Raanani, Ofir Wolach, Eitan Kugler

Blood (2023) 142 (Supplement 1): 5911.

https://doi.org/10.1182/blood-2023-185488

Published: 2023

Journal Articles

Defining Current Patterns of Blood Product Use during Intensive Induction Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients

Liron Miller, Mor Freed-Freundlich, Tamer Hellou, Avichai Shimoni, Abraham Avigdor, Mudi Misgav, Jonathan Canaani

Blood (2022) 140 (Supplement 1): 5717–5718.

https://doi.org/10.1182/blood-2022-156096

Published: 2022

Journal Articles

The Occurrence of Thrombosis during Intensive Chemotherapy Treatment for Acute Myeloid Leukemia Patients Does Not Impact on Long-Term Survival

Tamer Hellou, Omri Cohen, Abraham Avigdor, Avichai Shimoni, Mudi Misgav, Jonathan Canaani

Blood (2022) 140 (Supplement 1): 3229–3230.

https://doi.org/10.1182/blood-2022-156099

Published: 2022

Journal Articles

Clinical Predictors for Relapse Among Patients with AML Who Responded to Venetoclax-Based Treatment - a Real-World Prospective Analysis from the Revive Study Group

Blood (2022) 140 (Supplement 1): 9002–9004.

https://doi.org/10.1182/blood-2022-162140

Published: 2022

Journal Articles

Interim Results from Clevo: A Non-Interventional Cohort Study Investigating the Clonal Evolution of FMS-like Tyrosine Kinase 3 ( FLT3 ) Mutations during Disease Progression in Patients with Acute Myeloid Leukemia

Cristina Papayannidis, Blanca Boluda, Jonathan Canaani, Pascal Turlure, Ann De Becker, Anand Tandra, Dina Elsouda, Arnaud Houweling, Anil Upadhyay, Isabelle Wouters, Paresh Vyas

Blood (2022) 140 (Supplement 1): 11641–11643.

https://doi.org/10.1182/blood-2022-156296

Published: 2022

Journal Articles

Utilization of Antifungal Prophylaxis and Treatment for Newly Diagnosed AML Patients Treated with Venetoclax Based Regimens in Routine Clinical Practice - a Prospective Analysis from the Revive Study

Blood (2022) 140 (Supplement 1): 6162–6164.

https://doi.org/10.1182/blood-2022-163020

Published: 2022

Journal Articles

Real World Prospective Observational Multicenter Trial of Venetoclax-Based Therapy for Patients with AML Reveals Unique Patterns of Patient Selection and Treatment Utilization - Revive Study

Ofir Wolach, Itai Levi, David Lavie, Jonathan Canaani, Sigal Tavor, Ilana Hellmann, Tamar Tadmor, Tsila Zuckerman, Galia Stemer, Jenia Berelovich, Keren Ofek, Neta Frankel, Moshe Grunspan, Yishai Ofran, Yakir Moshe

Blood (2021) 138 (Supplement 1): 1246.

https://doi.org/10.1182/blood-2021-147245

Published: 2021

Journal Articles

Acute Myeloid Leukemia Patients Requiring Two Cycles of Intensive Induction for Attainment of Remission Experience Inferior Survival Compared with Patients Requiring a Single Course of Induction Chemotherapy

Gal Sharvit, Gabriel Heering, Maya Zlotnick, Arnon Nagler, Abraham Avigdor, Avichai Shimoni, Jonathan Canaani

Blood (2021) 138 (Supplement 1): 3390.

https://doi.org/10.1182/blood-2021-145552

Published: 2021

Journal Articles

ELN 2017 Classification Significantly Impacts on the Risk of Early Death in Acute Myeloid Leukemia Patients Receiving Intensive Induction Chemotherapy

Naama Keren Froim, Gabriel Heering, Gal Sharvit, Maya Zlotnick, Arnon Nagler, Avichai Shimoni, Abraham Avigdor, Jonathan Canaani

Blood (2021) 138 (Supplement 1): 3392.

https://doi.org/10.1182/blood-2021-145551

Published: 2021

Journal Articles

First Results from a Nationwide Prospective Non-Interventional Study of Venetoclax-Based 1 st Line Therapies in Patients with Acute Myeloid Leukemia (AML) - Revive Study

Ofir Wolach, MD, Itai Levi, MD, Jonathan Canaani, MD, Tamar Tadmor, MD, Sigal Tavor, MD, Ilana Hellmann, MD, Tsila Zuckerman, MD, David Lavie, MD, Galia Stemer, MD, Raanan Cohen, MD, Ran Afik, PhD, Keren Ofek, PhD, Hilla Banayan, BSc MBA, Inna Kan, PhD, Moshe Grunspan, PhD, Yishai Ofran, MD, Yakir Moshe, MD PhD

Blood (2020) 136 (Supplement 1): 27–28.

https://doi.org/10.1182/blood-2020-139923

Published: 2020

Journal Articles

Evaluating Outcomes of Adult Patients with Acute Lymphoblastic Leukemia Treated on the GMALL Protocol

Danielle Fredman, Yulia Volchek, MD, Gabriel Heering, Keren Shichrur, PhD, Ronit Yerushalmi, MD, Noga Shem-Tov, MD, Elena Ribakovsky, MD, Avichai Shimoni, MD, Abraham Avigdor, MD, Arnon Nagler, MD, Jonathan Canaani, MD

Blood (2020) 136 (Supplement 1): 28–29.

https://doi.org/10.1182/blood-2020-134771

Published: 2020

Journal Articles

A Phase II Study of Bisantrene in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Jonathan Canaani, MD, Ivetta Danilesko, MD, Noga Shem-Tov, MD, Maya Zlotnick, MD, Kira Lozinsky, Ohad Benjamini, Ronit Yerushalmi, MD, Meital Nagar, PhD, Chen Dor, PhD, Avichai Shimoni, MD, Abraham Avigdor, MD, Arnon Nagler, MD

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-135947

Published: 2020

Journal Articles

Donor Age Determines Outcome in Acute Leukemia Patients Undergoing Haploidentical Hematopoietic Cell Transplantation

Jonathan Canaani, MD, Bipin N. Savani, MD, Myriam Labopin, MD, Xiao Jun Huang, Fabio Ciceri, MD, William Arcese, MD, Yener Koc, MD, Johanna Tischer, MD, Didier Blaise, Zafer Gulbas, MD, Maria Teresa Van Lint, MD, Benedetto Bruno, Mohamad Mohty, MD PhD, Arnon Nagler, MD

Blood (2017) 130 (Supplement 1): 850.

https://doi.org/10.1182/blood.V130.Suppl_1.850.850

Published: 2017

Journal Articles

Haploidentical Stem Cell Transplantation Attenuates the Prognostic Impact of FLT3-ITD in Acute Myeloid Leukemia

Jonathan Canaani, MD, Myriam Labopin, MD, Xiao Jun Huang, William Arcese, MD, Fabio Ciceri, MD, Didier Blaise, MD PhD, Giuseppe Irrera, Lucia Lopez Corral, Benedetto Bruno, MD PhD, Stella Santarone, MD, Maria Teresa van Lint, Antonin Vitek, MDPhD, Jordi Esteve, MD PhD, Mohamad Mohty, MD PhD, Arnon Nagler, MD

Blood (2017) 130 (Supplement 1): 4584.

https://doi.org/10.1182/blood.V130.Suppl_1.4584.4584

Published: 2017

Journal Articles

Mechanisms of Acquired Resistance to Gilteritinib Therapy in Relapsed and Refractory FLT3 -Mutated Acute Myeloid Leukemia

Christine M. McMahon, MD, Jonathan Canaani, MD, Bryan Rea, MD, Rachel Lynn Sargent, MD, Jennifer J.D. Morrissette, PhD, David B. Lieberman, MS, CGC, Christopher Watt, MD PhD, Gregory W. Schwartz, PhD, Robert B. Faryabi, PhD, Timothy T. Ferng, MD, Neil P. Shah, MD PhD, Catherine C. Smith, MD, Martin Carroll, MD, Alexander E. Perl, MD

Blood (2017) 130 (Supplement 1): 295.

https://doi.org/10.1182/blood.V130.Suppl_1.295.295

Published: 2017

Journal Articles

Impact of FAB Classification on Predicting Outcome in Acute Myeloid Leukemia, Not Otherwise Specified, Patients Undergoing Allogeneic Stem Cell Transplantation in CR1: An Analysis of 1690 Patients from the Acute Leukemia Working Party of EBMT

Jonathan Canaani, MD, Eric Beohou, Myriam Labopin, Gerard Socie, MD PhD, Anne Huynh, MD, Liisa Volin, MD PhD, Jan J. Cornelissen, MD PhD, Noel Milpied, MD PhD, Tobias Gedde-Dahl, Eric Deconinck, MD PhD, Jeremy Delage, MD, Didier Blaise, MD PhD, Mohamad Mohty, MD PhD, Arnon Nagler

Blood (2016) 128 (22): 2899.

https://doi.org/10.1182/blood.V128.22.2899.2899

Published: 2016

Journal Articles

Outcome of Patients with Acute Myeloid Leukemia Treated with Salvage High-Dose Cytarabine Monotherapy

Jonathan Canaani, MD, Marlise R. Luskin, MD, Alison Loren, MD MS, Colleen Timlin, PharmD, BCOP, James Mangan, MD PhD, Elizabeth O. Hexner, MD, Noelle V. Frey, MDMS, David L Porter, MD, Edward A. Stadtmauer, MD, Selina Luger, MD

Blood (2015) 126 (23): 2543.

https://doi.org/10.1182/blood.V126.23.2543.2543

Published: 2015

Journal Articles

FGF-2 expands murine hematopoietic stem and progenitor cells via proliferation of stromal cells, c-Kit activation, and CXCL12 down-regulation

Tomer Itkin, Aya Ludin, Ben Gradus, Shiri Gur-Cohen, Alexander Kalinkovich, Amir Schajnovitz, Yossi Ovadya, Orit Kollet, Jonathan Canaani, Elias Shezen, Douglas J. Coffin, Grigori N. Enikolopov, Thorsten Berg, Wanda Piacibello, Eran Hornstein, Tsvee Lapidot

Blood (2012) 120 (9): 1843–1855.

https://doi.org/10.1182/blood-2011-11-394692

Published: 2012

Includes: Supplemental data

Journal Articles

Circadian Corticosterone Levels Regulate and Integrate Hematopoietic Stem and Progenitor Cell Function and Bone Remodeling Via Notch1 Signaling

Orit Kollet, PhD, Yaron Vagima, PhD, Karin Golan, MSc, Jonathan Canaani, MD, Gabriele D'Uva, MSc, Tomer Itkin, MSc, Alexander Kalinkovich, MD, PhD, Elias Shezen, PhD, Adi Neufeld-Cohen, MSc, Diana Rashkovan, MSc, Alon Chen, PhD, Tsvee Lapidot, PhD

Blood (2010) 116 (21): 840.

https://doi.org/10.1182/blood.V116.21.840.840

Published: 2010

NARROW

How I use Maintenance Therapy in Acute Myeloid Leukemia

Gilteritinib and Venetoclax for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia - a Real-World Multicenter Retrospective Study

Defining Current Patterns of Blood Product Use during Intensive Induction Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients

The Occurrence of Thrombosis during Intensive Chemotherapy Treatment for Acute Myeloid Leukemia Patients Does Not Impact on Long-Term Survival

Clinical Predictors for Relapse Among Patients with AML Who Responded to Venetoclax-Based Treatment - a Real-World Prospective Analysis from the Revive Study Group

Interim Results from Clevo: A Non-Interventional Cohort Study Investigating the Clonal Evolution of FMS-like Tyrosine Kinase 3 ( FLT3 ) Mutations during Disease Progression in Patients with Acute Myeloid Leukemia

Utilization of Antifungal Prophylaxis and Treatment for Newly Diagnosed AML Patients Treated with Venetoclax Based Regimens in Routine Clinical Practice - a Prospective Analysis from the Revive Study

Real World Prospective Observational Multicenter Trial of Venetoclax-Based Therapy for Patients with AML Reveals Unique Patterns of Patient Selection and Treatment Utilization - Revive Study

Acute Myeloid Leukemia Patients Requiring Two Cycles of Intensive Induction for Attainment of Remission Experience Inferior Survival Compared with Patients Requiring a Single Course of Induction Chemotherapy

ELN 2017 Classification Significantly Impacts on the Risk of Early Death in Acute Myeloid Leukemia Patients Receiving Intensive Induction Chemotherapy

First Results from a Nationwide Prospective Non-Interventional Study of Venetoclax-Based 1 st Line Therapies in Patients with Acute Myeloid Leukemia (AML) - Revive Study

Evaluating Outcomes of Adult Patients with Acute Lymphoblastic Leukemia Treated on the GMALL Protocol

A Phase II Study of Bisantrene in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Donor Age Determines Outcome in Acute Leukemia Patients Undergoing Haploidentical Hematopoietic Cell Transplantation

Haploidentical Stem Cell Transplantation Attenuates the Prognostic Impact of FLT3-ITD in Acute Myeloid Leukemia

Mechanisms of Acquired Resistance to Gilteritinib Therapy in Relapsed and Refractory FLT3 -Mutated Acute Myeloid Leukemia

Impact of FAB Classification on Predicting Outcome in Acute Myeloid Leukemia, Not Otherwise Specified, Patients Undergoing Allogeneic Stem Cell Transplantation in CR1: An Analysis of 1690 Patients from the Acute Leukemia Working Party of EBMT

Outcome of Patients with Acute Myeloid Leukemia Treated with Salvage High-Dose Cytarabine Monotherapy

FGF-2 expands murine hematopoietic stem and progenitor cells via proliferation of stromal cells, c-Kit activation, and CXCL12 down-regulation

Circadian Corticosterone Levels Regulate and Integrate Hematopoietic Stem and Progenitor Cell Function and Bone Remodeling Via Notch1 Signaling

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only